Hôpital Necker-Enfants Malades
Paris, 75015, France
Location status: Recruiting
NCT Number: NCT05390801
Congenital aniridia is a pan-ocular genetic disease characterized by a partial or complete absence of the iris, hence its name. The prevalence ranges from 1 / 40,000 to 1 / 96,000 births, but it may be underestimated. This condition combines several types of eye damage and could associate systemic manifestations, with a variable phenotype and genotype.
This study aims to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease through a survey prepared by ophthalmologists from the Ophthalmology Department of Necker-Enfants Malades Hospital, reference center in France for this pathology. The patient fills it out only once.
Interested in participating?
Request InfoAll sexes
Observational
Paris, 75015, France
Location status: Recruiting
Congenital aniridia is a pan-ocular genetic characterized by partial or complete absence of the iris, hence its name. The prevalence ranges from 1 / 40,000 to 1 / 96,000 births, but it may be underestimated. This condition combines several types of eye damage :
Congenital aniridia can also be associated with several severe systemic manifestations, including syndromic aniridia (WAGR syndrome and Gillespie syndrome).
The major gene responsible for autosomal dominant forms of congenital aniridia is PAIRED BOX GENE 6 (PAX6) (MIM#607108) with over 500 pathogenic variants reported to date.
Congenital aniridia is therefore a rare, pan-ocular disease associating systemic manifestations, with a variable phenotype and genotype.
This study aims to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease through a survey prepared by ophthalmologists from the Ophthalmology Department of Necker-Enfants Malades Hospital, reference center in France for this pathology. The patient fills it out only once.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Survey developed by ophthalmologists from the Ophthalmology Department of the Necker-Enfants Malades Hospital, fill out only once by patients with congenital aniridia in order to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease.
Time frame: 24 months
To identify eye and systemic manifestations in congenital aniridia through a survey prepared by ophthalmologists. The answers of the survey will be compared with data from the patient's medical file.
Time frame: 24 months
Descriptive analysis of the patient's answers and data from the patient's medical file to determine the impact of the disease on patient's autonomy.
Questions in the survey concerning patient's autonomy will be compared to the data collected in the medical file. For instance: help with activities of daily living, computer/phone use, lifestyle, outdoor and indoor travel, etc.
Time frame: 24 months
Descriptive analysis of the patient's answers and data from the patient's medical file to determine how well patients know their disease and potential complications.
Questions in the survey concerning the etiology, complications and evolution of the disease will be compared with the data collected in the medical file in order to determine the degree of knowledge of the patients of the disease.
Time frame: 24 months
To determine the influence of factors such as age, sex, origin and profession on patients' knowledge of their disease according to survey answers.
Time frame: 24 months
Descriptive analysis of the parents' answers and data from the patient's medical file to determine parents' knowledge of their child's disease and potential complications.
For patients < 18 years old, the parents' answers of the questions in the survey concerning the etiology, complications and evolution of the disease will be compared with the data collected in the medical file.
Contact information is provided by the study sponsor or research team.
Alejandra Daruich, MD, PhD
CONTACT
1 44 38 19 69 ext. +33
Hélène Morel
CONTACT
1 71 19 63 46 ext. +33
Assistance Publique - Hôpitaux de Paris
Other
Acronym: Aniridia-Quizz
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05909735
Aniridia, Congenital Abnormalities
Minneapolis, Minnesota, United States
View Trial DetailsNCT02945176
Aniridia, Burns
Cologne, Germany
View Trial DetailsNCT05954403
Aniridia, Anophthalmia
Paris, Île-de-France Region, France
View Trial DetailsNCT06491615
Albinism, Amino Acid Metabolism, Inborn Errors
Bethesda, Maryland, United States
View Trial Details